Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate to severe hidradenitis suppurativa
Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP)
An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - Nintedanib in PF-ILD (extension)
100 项与 SCS Boehringer Ingelheim Comm.V 相关的临床结果
0 项与 SCS Boehringer Ingelheim Comm.V 相关的专利(医药)
100 项与 SCS Boehringer Ingelheim Comm.V 相关的药物交易
100 项与 SCS Boehringer Ingelheim Comm.V 相关的转化医学